Actinium Pharmaceuticals Inc
Ownership
Ownership Structure
Who owns Actinium Pharmaceuticals Inc (ATNM)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.4% of the shares are freely tradable; institutional investors hold 20.6%.
Largest Shareholders
No ownership data is available for this stock yet.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Seth Sandesh | Chief Executive Officer | 1,965,355 | 2,751,497 $ | Sep 2, 2026 | direct |
| David Matthew T | Chief Financial Officer | 250,000 | 350,000 $ | Oct 14, 2026 | direct |
| Nicholson, C. David | Director | 63,300 | 88,620 $ | Sep 2, 2026 | direct |
| Steinhart Richard I | Director | 63,116 | 88,362 $ | Sep 2, 2026 | direct |
| Shetty Ajit | Director | 62,357 | 87,300 $ | Sep 2, 2026 | direct |
| Chell Jeffrey W. | Director | 61,600 | 86,240 $ | Sep 2, 2026 | direct |
| Almenoff June Sherie | Director | 18,000 | 25,200 $ | Sep 2, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 14, 2026 | David Matthew T | Chief Financial Officer | Other | 250,000 | 0.00 | – |
| Sep 2, 2026 | Nicholson, C. David | Director | Other | 62,800 | 0.00 | – |
| Sep 2, 2026 | Shetty Ajit | Director | Other | 61,600 | 0.00 | – |
| Sep 2, 2026 | Almenoff June Sherie | Director | Other | 18,000 | 0.00 | – |
| Sep 2, 2026 | Seth Sandesh | Chief Executive Officer | Other | 1,027,274 | 0.00 | – |
| Sep 2, 2026 | Seth Sandesh | Chief Executive Officer | Other | 753,600 | 0.00 | – |
| Sep 2, 2026 | Steinhart Richard I | Director | Other | 62,800 | 0.00 | – |
| Sep 2, 2026 | Chell Jeffrey W. | Director | Other | 61,600 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.